文献速递MDS 与骨髓增殖性肿瘤

衰弱与骨髓纤维化临床结局的关联:一项回顾性队列研究

Association of frailty with clinical outcomes in myelofibrosis: a retrospective cohort study.
PubMed 文献 · Br J Haematol · 2021-06-15

该回顾性队列研究纳入439例慢性期骨髓纤维化患者,使用35项衰弱指数将患者分为健康、衰弱前期和衰弱。多因素分析显示,衰弱前期和衰弱患者总生存期更短,且在JAK抑制剂治疗亚组中衰弱与更高的治疗失败累积发生率相关。衰弱评分优于年龄、合并症和体能状态。

要点

  • 衰弱评估优于年龄、合并症和ECOG体能状态

核心结论

  • 更高的衰弱评分与骨髓纤维化患者更差的总生存期和增加的JAK抑制剂治疗失败相关。
  • 衰弱是比年龄、合并症和体能状态更优的体能指标。

主要发现

  • 年龄、合并症、ECOG体能状态和MPN驱动突变未影响结局。

临床怎么用

  • 在骨髓纤维化患者中应评估衰弱状态,以识别总生存期较差和JAK抑制剂治疗失败风险较高的患者。
  • 衰弱评估可作为优于年龄、合并症和体能状态的体能指标,辅助临床决策。

局限性

  • 回顾性研究设计可能引入选择偏倚和信息偏倚。
  • 单中心数据可能限制结果的普遍性。
  • 衰弱指数基于35项变量,未报告变量具体构成。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There is limited understanding of the impact of frailty on clinical outcomes in patients with myelofibrosis (MF). In this retrospective cohort study on 439 chronic phase MF patients [mean age: 68·7 ± 12 years; median follow-up: 3·4 years (IQR 0·4-8·6)] from 2004 till 2018, we used a 35-variable frailty index (FI) to categorise patient's frailty status as fit (FI < 0·2, reference), prefrail (FI 0·2-0·29) or frail (FI ≥ 0·3). The association of frailty with overall survival (OS) and cumulative JAK inhibitor (JAKi) therapy failure was measured using hazard ratio (HR, 95% CI). In multivariable analysis, prefrail (HR 1·7, 1·1-2·5) and frail patients (HR 2·9, 1·6-5·5), those with higher DIPSS score (HR 2·5, 1·6-3·9) and transfusion dependency (HR 1·9, 1·3-2·9) had shorter OS. In a subset analysis of patients on JAKi treatment (n = 222), frail patients (HR 2·5, 1·1-5·7), patients with higher DIPSS score (HR 1·7, 1·0-3·1) and transfusion dependence (HR 1·7, 1·1-2·7) had higher cumulative incidence of JAKi failure. Age, comorbidities, ECOG performance status, and MPN driver mutations did not impact outcomes. Thus, higher frailty scores are associated with worse OS and increased JAKi failure in MF, and is a superior indicator of fitness in comparison to age, comorbidities, and performance status.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Bankar A, Alibhai S, Smith E, et al. Association of frailty with clinical outcomes in myelofibrosis: a retrospective cohort study. Br J Haematol. 2021. PMID: 34131896. doi:10.1111/bjh.17617

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。